Shares of Teva Pharmaceuticals ( TEVA - Free Report ), a favorite for investors chasing large dividend yields, fell more than 4.4%—and hit a 10-year intraday low—on Wednesday. Just says after the company reported sluggish Q2 earnings, investors are continuing to ditch the stock amid reports that Teva is desperately trying to sell off assets. According to sources cited by Bloomberg, Teva is looking to ramp up asset sales in an effort to preserve its credit rating and cut its mounting debt. The report claims that Medis, an Iceland-based generic drug manufacturer, is one of the Teva units on the table. Bloomberg also claimed that Teva is considering the sale of its respiratory treatment assets, although the publication's anonymous sources said that a decision to sell has not been finalized and considerations are still at an early stage. "Teva is looking at every opportunity to focus our business and streamline operations processes and structure," the company said in a statement.